載入中
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
最新資料
¥696
+¥51.00 · +7.91%
盤中時間採用JST。市場資料可能有所延遲。
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
日內區間
目前¥696
52週區間
目前¥696
盤中時間採用JST。市場資料可能有所延遲。
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
日內區間
目前¥696
52週區間
目前¥696
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（JPY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7221.5萬 JPY | 8003.8萬 JPY | 6925萬 JPY | 3.92億 JPY | 2.9億 JPY |
| 銷貨成本 | — | — | — | 8841.3萬 JPY | 7159.8萬 JPY |
| 毛利 | 7221.5萬 JPY | — | — | 3.03億 JPY | 2.18億 JPY |
| 研究與開發 | 6.81億 JPY | 6.43億 JPY | 7.17億 JPY | 5.33億 JPY | 3.99億 JPY |
| 銷售、一般及管理費用 | 3億 JPY | 2.55億 JPY | 2.41億 JPY | 1.96億 JPY | 1.78億 JPY |
| 營業費用 | 9.82億 JPY | 8.98億 JPY | 9.58億 JPY | 7.3億 JPY | 5.76億 JPY |
| 利息收入 | 17.9萬 JPY | 18.9萬 JPY | 5000 JPY | — | 1000 JPY |
| 營業利益 | −9.09億 JPY | −8.18億 JPY | −8.89億 JPY | −4.26億 JPY | −3.58億 JPY |
| 淨利 | −9.16億 JPY | −7.56億 JPY | −8.54億 JPY | −3.32億 JPY | −3.01億 JPY |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
